ReviewEMBO reports2009
Towards a small animal model for hepatitis C.
Review in EMBO reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Characterization of RNA Sensing Pathways in Hepatoma Cell Lines and Primary Human Hepatocytes.Cells · 2021Article
- The interaction between mitochondria and oncoviruses.Biochimica et biophysica acta. Molecular basis of disease · 2018Review
- TIM-1 Promotes Hepatitis C Virus Cell Attachment and Infection.Journal of virology · 2017Article
- Superficial vimentin mediates DENV-2 infection of vascular endothelial cells.Scientific reports · 2016Article
- In vivo models of hepatitis B and C virus infection.FEBS letters · 2016Review
- Hepatitis C virus utilizes VLDLR as a novel entry pathway.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- The Serum Very-Low-Density Lipoprotein Serves as a Restriction Factor against Hepatitis C Virus Infection.Journal of virology · 2015Article
- Hepatitis C virus structural proteins can exacerbate or ameliorate acetaminophen-induced liver injury in mice.Archives of toxicology · 2015Article
- Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war?World journal of gastroenterology · 2015Review
- Visualizing hepatitis C virus infection in humanized mice.Journal of immunological methods · 2014Review
- Transient replication of Hepatitis C Virus sub-genomic RNA in murine cell lines is enabled by miR-122 and varies with cell passage.PloS one · 2014Article
- Article
- Development of murine models to study Hepatitis C virus induced liver pathogenesis.Indian journal of virology : an official organ of Indian Virological Society · 2013Article
- Genetic and functional characterization of the N-terminal region of the hepatitis C virus NS2 protein.Journal of virology · 2013Article
- Study of hepatitis C virus entry in genetically humanized mice.Methods (San Diego, Calif.) · 2013Article
- Evidence for novel hepaciviruses in rodents.PLoS pathogens · 2013Article
- Article
- Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells.Journal of virology · 2012Article
- New hepatitis C virus drug discovery strategies and model systems.Expert opinion on drug discovery · 2012Review
- Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Hepatitis C virus (HCV) causes chronic liver disease and affects an estimated 3% of the world's population. Options for the prevention or therapy of HCV infection are limited; there is no vaccine and the nonspecific, interferon-based treatments now in use are frequently ineffective and have significant side effects. A small-animal model for HCV infection would significantly expedite antiviral compound development and preclinical testing, as well as open new avenues to decipher the mechanisms that underlie viral pathogenesis. The natural species tropism of HCV is, however, limited to humans and chimpanzees. Here, we discuss the prospects of developing a mouse model for HCV infection, taking into consideration recent results on HCV entry and replication, and new prospects in xenotransplantation biology. We highlight three independent, but possibly complementary, approaches towards overcoming current species barriers and generating a small-animal model for HCV pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.